Earnings Estimate Revisions for Nevro This maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share for the fiscal year ending December 2024, which ...

This Zacks Rank #3 (Hold) company’s shares have lost 80.7% in the year-to-date period against the industry’s 5.2% growth. The S&P 500 has increased 27.7% in the said time frame. The renowned ...

The company started 2025 on a solid note, driven by a decent guidance for the year, but a deal for loss-making Nevro creates some discomfort among investors. All this makes me intrigued to watch ...

In the latest quarter, 11 analysts provided ratings for Nevro NVRO, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving ...

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to Neutral. As of January 28, 2025, the average one-year price target for Nevro ...

Scavilla announced the acquisition of Nevro Corporation for $250 million, aimed at expanding Globus' reach into the $2 billion neuromodulation market. He stated, "Nevro technology offers ...

Nevro (NVRO) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.15 per share a year ago. These figures are ...

REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...

Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...